Delveinsight

AUGUST 2, 2020

The company has also signed a licensing agreement with Ono Pharmaceutical , a Japanese pharma company, transferring exclusive rights to develop and commercialise anamorelin in Japan, South Korea, and Taiwan. Cancer Cachexia Pipeline. Apart from the products as mentioned earlier, Tetra Bio?

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

JUNE 16, 2021

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, its HER2-targeting antibody drug conjugate (ADC).

Antibody 59

Antibody Sales Drugs Trials 59

pharmaphorum

JANUARY 29, 2021

Lilly is paying $20 million upfront for exclusive rights to AK1780, a P2X7 receptor antagonist in early-stage clinical development for neuroinflammatory pain conditions, outside Japan and China. While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

pharmaphorum

SEPTEMBER 8, 2022

It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). The company stated that there was “no indication of risk,” but it meant that the rollout and the clinical development of Pluvicto was hampered.

Manufacturing 105

Manufacturing Development Antibody Drugs 105

pharmaphorum

NOVEMBER 12, 2020

The mid-sized pharma group has also signed a collaboration with Florida, US-based Lacerta Therapeutics , adding more AAV capsids – well established as a staple for delivering gene therapy sequences – as well as another gene therapy candidate.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

XTalks

AUGUST 18, 2021

These samples are often made available to support the research efforts of pharma companies developing new antibacterial agents. In addition to drug discovery and development, isolates can also be used in the design and testing of rapid diagnostics tools, and can inform site selection during the clinical trials process.

Development 105

Development Bacteria Drugs Vaccination 105

pharmaphorum

DECEMBER 23, 2020

Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. This is a rare disease that affects the kidney but is caused by overproduction of antibodies produced in the lining of the small intestine, for which there are no approved medications. Rare disease progress.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

Delveinsight

NOVEMBER 29, 2020

Key players such as Novartis , Annexin Pharmaceuticals , Gene Signal , Ocular Therapeutics , and Asclepix Therapeutics along with other pharma companies are investigating their candidates proactively in a quest to launch their therapies as soon as possible in the Retinal vein occlusion market.

Marketing 52

Marketing Drug Delivery Pharma Companies Clinical Trials 52

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. How big pharma tackles rare diseases.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

XTalks

JUNE 25, 2024

In the past two years, the industry has faced considerable challenges due to a constrained financing environment, forcing many emerging and early-stage biotech companies to restructure their operations, merge with other companies or narrow their research and development (R&D) efforts by shelving certain assets.

Pharma Companies 52

Pharma Companies Production FDA Approval Vaccination 52

pharmaphorum

MAY 14, 2021

This and its smaller size – it’s a “nanobody” that is only a fraction of the size of conventional antibodies – could allow it to penetrate deeper into the skin and joints. It’s extremely possible a pharma company may want to partner and it can have many forms. is the future in inflammatory diseases.”.

Drugs 66

Drugs Licensing Licensing Development 66

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group.

Development 52

Development Gene Therapy Engineer Life Science 52

Delveinsight

AUGUST 17, 2020

million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence. The Gastroparesis market size in the 7MM was found to be USD 3,170.01 FDA for a phase 2b study in diabetic kidney disease (DKD).

Marketing 54

Marketing Trials FDA Approval Clinical Development 54

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. VBL is currently advancing its lead anti-MOSPD2 candidate through IND-enabling studies.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

Roots Analysis

MAY 21, 2024

Due to which, several big pharma companies and other industry stakeholders are actively contributing towards development of protein degradation therapies and technologies, contributing towards growth of targeted protein degradation market.

Protein 40

Protein Marketing Development Antibody 40

XTalks

MARCH 11, 2025

Emerging evidence indicates that a multivalent mRNA vaccine encoding hemagglutinin antigens from all known influenza virus subtypes can elicit broad, cross-reactive antibody responses in animal models, demonstrating the potential of mRNA platforms to overcome challenges posed by antigenically variable viruses.

Vaccine 64

Vaccine Vaccination Development Manufacturing 64

The Pharma Data

DECEMBER 16, 2020

the company is exploring other ways to combat COVID-19. AstraZeneca is partnering with INOVIO and multiple universities to advance INOVIO’s innovative DNA-encoded monoclonal antibody (dMAb) technology. Recombinant monoclonal antibodies are designed to enhance the immune system’s ability to regulate cell functions.

Vaccine 52

Vaccine Vaccination DNA Antibody 52